Elahere Disease Interactions

The use of mirvetuximab soravtansine should be avoided in patients with moderate or severe hepatic impairment. No dose adjustment is recommended for patients with mild hepatic impairment.

Mirvetuximab soravtansine caused peripheral neuropathy in 36% of the patients in clinical trials. Monitor patients closely for signs and symptoms of neuropathy, such as paresthesia, tingling or burning sensation, neuropathic pain, muscle weakness, or dysesthesia. For patients experiencing new or worsening peripheral neuropathy, withhold dosage, dose reduce, or permanently discontinue treatment based on the severity of the symptoms.

The effect of severe renal impairment (CrCl 15 to less than 30 mL/min) or end-stage renal disease on mirvetuximab soravtansine is unknown. Caution is advised if prescribing to these patients. No dosage adjustment is recommended for patients with mild to moderate renal impairment.

Mirvetuximab soravtansine can cause severe ocular adverse reactions, including visual impairment, keratopathy (corneal disorders), dry eye, photophobia, eye pain, and uveitis. Patients should have a detailed ophthalmic exam including visual acuity and slit lamp exam prior to treatment initiation, and before every other cycle for the first 8 cycles, and then as clinically indicated. Refer patients to an eye care professional immediately for any new or worsening ocular signs and symptoms. Monitor closely for ocular toxicity and withhold, reduce, or permanently discontinue treatment based on severity and persistence of ocular adverse reactions.